论文信息 - The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

[1] C. Grady,et al. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. , 2009, Journal of the National Cancer Institute.

[2] Joseph E. Stiglitz,et al. The Price of Inequality , 2012 .

[3] Thomas J. Smith,et al. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4] M. Höglund,et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5] K. Rascati. The $64,000 question--what is a quality-adjusted life-year worth? , 2006, Clinical therapeutics.

[6] H. Kantarjian,et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 , 2013, Leukemia & lymphoma.

[7] S. Giralt,et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? , 2008, Bone Marrow Transplantation.

[8] J. Lexchin,et al. Pharmaceutical research and development: what do we get for all that money? , 2012, BMJ : British Medical Journal.

[9] S. Zenios,et al. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10] References , 1971 .

[11] H. Kantarjian,et al. The Chronic Leukemias , 2011 .

[12] Jeffrey Aronson,et al. The $800 Million Pill: The Truth Behind the Cost of New Drugs , 2004, BMJ : British Medical Journal.

[13] Elizabeth Warren,et al. Medical bankruptcy in the United States, 2007: results of a national study. , 2009, The American journal of medicine.

[14] A. Nagler,et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.

[15] Merrill Goozner,et al. The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[16] R. Slater,et al. Magic cancer bullet : how a tiny orange pill is rewriting medical history , 2003 .

[17] D. Himmelstein,et al. Cost control in a parallel universe: Medicare spending in the United States and Canada. , 2012, Archives of internal medicine.

[18] G. Cerri,et al. Latin America , 2000, Ultrasound in medicine & biology.

[19] H. Kantarjian,et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2012, Cancer.